[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362869-105":59,"doc-detail-362869-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-esmosiog-cancer-in-the-elderly-working-group-pragmatic-strategies-for-clinical-trial-designs-and-endpoints-in-older-adults-with-cancer","The ESMO/SIOG Cancer in the Elderly Working Group - pragmatic strategies for clinical trial designs and endpoints in older adults with cancer","","Cancer primarily affects older adults, yet patients aged 70 years or older remain under-represented in contemporary clinical trials, even without explicit age restrictions. Limited trial programs for older people with cancer are linked to clinician, patient, and sponsor-related bias. This review reports consensus-based, pragmatic strategies proposed by the ESMO/SIOG Cancer in the Elderly Working Group to improve clinical trial design and endpoints, thereby supporting participation, recruitment, and retention of older adults.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-esmosiog-cancer-in-the-elderly-working-group-pragmatic-strategies-for-clinical-trial-designs-and-endpoints-in-older-adults-with-cancer/362869/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-esmosiog-cancer-in-the-elderly-working-group-pragmatic-strategies-for-clinical-trial-designs-and-endpoints-in-older-adults-with-cancer/362869.png","ImageObject",300,407,{"name":92,"@type":93},"นรินทร์","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are older adults under-represented in cancer clinical trials?","Question",{"text":112,"@type":113},"Patients aged 70 years or older are under-represented even when no age restrictions exist. The review attributes limitations to clinician, patient, and sponsor bias, as well as restricted dedicated trial programs.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What methods did the ESMO/SIOG working group use to develop strategies?",{"text":117,"@type":113},"The working group convened international experts and used expert panel discussions grounded in a review of the evidence to reach consensus on trial design and endpoint strategies.",{"name":119,"@type":110,"acceptedAnswer":120},"What barriers and strategies does the review identify for trial participation?",{"text":121,"@type":113},"Barriers include strict eligibility criteria, poor trial design, time-consuming procedures, age bias, toxicity concerns, patient preferences, caregiver influences, and the digital divide. Strategies include streamlining recruitment, enhancing patient support, leveraging digital tools, and engaging caregivers and patient advocates.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362869,1790928049,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","REVIEW  \nThe ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer  \nC. Baldini1 , 2†∗, A. R. A. Mislang3 , 4†∗, K.-L. Cheung5, S. Pilleron6, H. Wildiers7, S. Rostoft8 , 9, N. R. Neuendorff10,  \nM. Frelaut11, R. Kanesvaran12, D. Papamichael13, S. O’Hanlon14 , 15, M. Puts16 , 17, F. Canoui-Poitrine18, 19, 20, L. Dal Lago21, W. K. Soo22, 23, 24, A. O’Donovan25, F. Gomes26, 27, L. Cooper28, 29, B. Canin30, 31, M. Bringuier32, 33, N. M. L. Battisti34,  \nL. Biganzoli35‡ & E. Brain33‡, on behalf of the ESMO/SIOG Cancer in the Elderly Working Group  \n1Drug Development Department (DITEP), Gustave Roussy, Villejuif; 2Paris Saclay University, Villejuif, France; 3College of Medicine and Public Health, Flinders University, Bedford Park; 4Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Adelaide, Australia; 5School of Medicine, University of Nottingham, Nottingham, UK; 6Ageing, Cancer, and Disparities Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg; 7Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; 8Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo; 9Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway; 10Department of Geriatrics, Marien Hospital Herne, University Hospital, Ruhr University Bochum, Herne, Germany; 11Department of Medical Oncology, Gustave Roussy, Villejuif, France; 12Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; 13Department of Medical Oncology, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; 14Department of Geriatric Medicine, Mater Private Network, Dublin; 15University College Dublin, Dublin, Ireland; 16Lawrence Bloomberg Faculty of Nursing, University of Toronto, Toronto; 17Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, Canada; 18Service de Santé Publique, GHU AP-HP Hôpitaux Universitaires Henri-Mondor, Créteil; 19UMR U955 — UPEC/Inserm U955, Faculté de Médecine de Créteil, Créteil; 20Département Masters, Faculté de Santé — UPEC, Créteil, France; 21Medical Oncology Department — Chirec Cancer Institute, Brussels, Belgium; 22Eastern Health Clinical School, Monash University, Box Hill; 23Cancer Services, Eastern Health, Box Hill; 24Aged Medicine Program, Eastern Health, Box Hill, Australia; 25Applied Radiation Therapy Trinity, Trinity St James’s Cancer Institute, Trinity College Dublin, Dublin, Ireland; 26Medical Oncology Department, The Christie NHS Foundation Trust, Manchester; 27Senior Adult Oncology, The Christie NHS Foundation Trust, Manchester, UK; 28Department of Geriatric Medicine, Rabin Medical Center, Petah Tikva; 29Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 30CARinG SCOREboard, City of Hope; 31Breast Cancer Options, Kingston, USA; 32Department of Supportive Care, Institut Curie/Saint-Cloud, Saint-Cloud; 33Department of Medical Oncology, Institut Curie/Saint-Cloud, Saint-Cloud, France; 34Department of Medicine, Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK; 35Department of Medical Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy  \nAvailable online 23 February 2026  \nBackground: Despite cancer affecting mostly older people, patients aged 70 years or older are under-represented in contemporary trials even in the absence of age restrictions. Moreover, trials dedicated to older adults with cancer, including geriatric assessment and management, are limited because of either clinician, patient, or sponsor bias. This article outlines pragmatic strategies to improve trial design and endpoints to facilitate participation of older adults with cancer in clinical trials.  \nMethods: The joint European Society for Medical Oncology (ESMO) and International Society of Geriatric Oncology (SIOG) Cancer in the Elderly Working Group assembled a group of international expe","cbCaiiA8io7zU41t","https://ap.wps.com/l/cbCaiiA8io7zU41t","pdf",981390,13,"English","# Background\n# Methods\n# Results\n## Barriers to trial participation\n## Strategies for accrual and retention","[{\"question\":\"Why are older adults under-represented in cancer clinical trials?\",\"answer\":\"Patients aged 70 years or older are under-represented even when no age restrictions exist. The review attributes limitations to clinician, patient, and sponsor bias, as well as restricted dedicated trial programs.\"},{\"question\":\"What methods did the ESMO/SIOG working group use to develop strategies?\",\"answer\":\"The working group convened international experts and used expert panel discussions grounded in a review of the evidence to reach consensus on trial design and endpoint strategies.\"},{\"question\":\"What barriers and strategies does the review identify for trial participation?\",\"answer\":\"Barriers include strict eligibility criteria, poor trial design, time-consuming procedures, age bias, toxicity concerns, patient preferences, caregiver influences, and the digital divide. Strategies include streamlining recruitment, enhancing patient support, leveraging digital tools, and engaging caregivers and patient advocates.\"}]","The ESMO/SIOG Cancer in the Elderly Working Group - pragmatic strategies for clinical trial designs and endpoints in older adults with cancer | PDF",1790149272,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b90f67466e6c01711a6aa1ac8a50759a.webp",983,1269,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7e7c1ac42162d18e1c3f1de0f541cf0.webp",982,1268,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3ea1785fff76c73dcc860ee893bbc80.webp",981,1266,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5f91bdb7179a28173b3eff161d9d474.webp",980,1265]